Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a $22 price target.
August 09, 2024 | 10:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals and maintained a $22 price target.
The reiteration of a Buy rating and the maintenance of a $22 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100